These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22227649)

  • 21. Rheumatoid arthritis: fish oil? Or snake oil?
    Lau C; Gallacher C; Ross P; Belch J
    Br J Rheumatol; 1991 Feb; 30(1):72-3. PubMed ID: 1991228
    [No Abstract]   [Full Text] [Related]  

  • 22. Speed, Safety, and Industry Funding - From PDUFA I to PDUFA VI.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2017 Dec; 377(23):2278-2286. PubMed ID: 29211663
    [No Abstract]   [Full Text] [Related]  

  • 23. Variations in time of market exclusivity among top-selling prescription drugs in the United States.
    Wang B; Liu J; Kesselheim AS
    JAMA Intern Med; 2015 Apr; 175(4):635-7. PubMed ID: 25664700
    [No Abstract]   [Full Text] [Related]  

  • 24. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
    McKenney JM; Sica D
    Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular disease and omega-3s: Prescription products and fish oil dietary supplements are not the same.
    Gutstein AS; Copple T
    J Am Assoc Nurse Pract; 2017 Dec; 29(12):791-801. PubMed ID: 29280361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Prescription Drug User Fee Act of 1992: speeding up the drug approval process.
    Bierut MB
    Healthspan; 1992 Dec; 9(11):12-4. PubMed ID: 10123552
    [No Abstract]   [Full Text] [Related]  

  • 27. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates.
    Berndt ER; Gottschalk AH; Philipson TJ; Strobeck MW
    Nat Rev Drug Discov; 2005 Jul; 4(7):545-54. PubMed ID: 16052239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: A Narrative Review.
    Hilleman DE; Wiggins BS; Bottorff MB
    Adv Ther; 2020 Feb; 37(2):656-670. PubMed ID: 31919792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDA and drug safety: new Tufts study challenges critics of the Prescription Drug User Fee Act.
    Lee R
    J Law Med Ethics; 2006; 34(1):131-4. PubMed ID: 16489994
    [No Abstract]   [Full Text] [Related]  

  • 30. User fees and beyond--the FDA Safety and Innovation Act of 2012.
    Kramer DB; Kesselheim AS
    N Engl J Med; 2012 Oct; 367(14):1277-9. PubMed ID: 23034017
    [No Abstract]   [Full Text] [Related]  

  • 31. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
    Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
    BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Omega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.
    Fialkow J
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):229-239. PubMed ID: 27138439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug safety on trial.
    Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
    [No Abstract]   [Full Text] [Related]  

  • 34. Omega-3 polyunsaturated fatty acids (Omacor) for hypertriglyceridemia.
    Med Lett Drugs Ther; 2005 Nov; 47(1221):91. PubMed ID: 16267495
    [No Abstract]   [Full Text] [Related]  

  • 35. New drug law to speed scientific review.
    Nature; 1992 Oct; 359(6396):563. PubMed ID: 1406977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 37. When to take statins; Lovaza versus OTC fish oil supplements.
    DeDea L
    JAAPA; 2011 May; 24(5):23. PubMed ID: 21574527
    [No Abstract]   [Full Text] [Related]  

  • 38. The effect of 'MaxEPA' in the treatment of patients with Behçet's disease.
    Kürkçüoğlu N; Tandoğdu R
    Br J Dermatol; 1989 Nov; 121(5):667-8. PubMed ID: 2597640
    [No Abstract]   [Full Text] [Related]  

  • 39. Upcoming market catalysts in Q4 2019.
    Ranj T
    Nat Rev Drug Discov; 2019 Sep; 18(10):738. PubMed ID: 31570850
    [No Abstract]   [Full Text] [Related]  

  • 40. [Medication prices in Germany--how are they determined?].
    Bruhn C
    Dtsch Med Wochenschr; 2010 Oct; 135(39):p34. PubMed ID: 20922657
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.